Skip to main content

Table 3 ARS is an independent predictor for the recurrence of early-stage LUAD

From: Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma

Parameters

Univariate Cox

Multivariate Cox

HR (95% CI)

P value

HR (95% CI)

P value

Gender (male vs. female)

1.045 (0.676–1.616)

0.842

1.128 (0.720–1.769)

0.599

Age (< = 65 vs. > 65)

1.203 (0.742–1.951)

0.453

1.291 (0.793–2.103)

0.305

Stage (stage I vs. stage II)

1.814 (1.165–2.825)

0.008

1.884 (0.669–5.302)

0.230

T (T1–2 vs. T3)

4.018 (2.051–7.870)

 < 0.001

2.457 (0.766–7.878)

0.131

N (N0 vs. N1)

1.174 (0.703–1.962)

0.540

0.728 (0.244–2.171)

0.569

Smoking (no vs. yes)

1.178 (0.650–2.134)

0.589

1.384 (0.747–2.563)

0.301

ARS (low vs. high)

1.341 (1.044–2.129)

0.039

1.291 (1.007–2.069)

0.044

  1. ARS acelylation-related score, HR hazard ratio, CI confidence interval, LUAD lung adenocarcinoma
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us